BRANFORD, Conn.--(BUSINESS WIRE)--Neurogen Corporation (Nasdaq: NRGN) today announced that development activities for MK-2295 (NGD-8243) will continue, based on promising preliminary results from proof-of-concept studies in its collaboration with Merck & Co, Inc., through an affiliate (collectively, “Merck”), to research, develop, and commercialize small molecule medicines which work by targeting the vanilloid receptor (VR-1). Neurogen also announced that the research portion of the collaboration will conclude on August 28, 2007. Merck will continue development of MK-2295 (NGD-8243) and will owe milestone payments and royalties to Neurogen upon the commercialization of any VR-1 compounds from the research program.
